Veracyte | VCYT - Des Atouts





Des Atouts Changement Date
Agenus USD 186.46M 40.34M 2026-03
Agilent USD 13.07B 252M 2026-03
Anika Therapeutics USD 179.39M 10.88M 2026-03
Arrowhead Research USD 2.27B 664.08M 2026-03
Bruker USD 6.13B 110.7M 2026-03
Heron Therapeutics USD 246.22M 9.66M 2026-03
Illumina USD 6.56B 85M 2026-03
Intrexon USD 73.16M 77.88M 2024-06
Karyopharm Therapeutics USD 108.42M 12.18M 2025-12
Laboratory Of America USD 19.09B 694.4M 2026-03
Ligand Pharmaceuticals USD 1.53B 28.53M 2026-03
Myriad Genetics USD 673.7M 32.9M 2026-03
Rigel Pharmaceuticals USD 242.53M 35.8M 2025-09
Roche Holding CHF 100.7B 5.94B 2025-12
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Siemens EUR 167.97B 2.16B 2026-03
Sonic Healthcare AUD 15.38B 550.57M 2024-12
Thermo Fisher Scientific USD 113.28B 2.94B 2026-03
Veracyte USD 1.44B 30.38M 2026-03
Waters USD 24.53B 19.45B 2026-03